" "
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Exceeds 2012 Goal for Placements of QIAsymphony Breakthrough Laboratory Automation System

Published: Thursday, January 10, 2013
Last Updated: Wednesday, January 09, 2013
Bookmark and Share
Growth of QIAsymphony, which offers full workflow solutions from biological sample to result, exceeds 750 placements..

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) has announced that it exceeded its goal for new placements of the QIAsymphony modular laboratory workflow platform in 2012. The growth of QIAsymphony, which offers full workflow solutions from biological sample to result, reached well more than 750 placements at the end of 2012, building on more than 550 at the end of 2011.

"We are very pleased to have exceeded our 2012 target for QIAsymphony, a breakthrough automation system that is improving laboratory workflows and accelerating the dissemination of molecular testing. We expect QIAsymphony to be a growth driver for QIAGEN over the next decade, and the strong uptake in the early years of its introduction is very positive," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "Customers in Molecular Diagnostics, Applied Testing and other types of molecular laboratories continue to respond positively to the cost-effective workflow and growing menu of test content for the QIAsymphony. We expect QIAsymphony placements to exceed 1,000 by the end of 2013 while also delivering on initiatives to expand the test menu, particularly in the United States and Europe, that will further increase the use of our consumables by customers."

QIAsymphony is an innovative, easy-to-use modular system that integrates a molecular laboratory's workflow from initial biological sample processing to final result. The QIAsymphony SP (sample preparation) and AS (assay setup) modules were introduced in 2008 and 2009, respectively, and in late 2010 QIAGEN launched the fully integrated QIAsymphony RGQ system that added the Rotor-Gene Q, the world's first rotary real-time PCR cycler, to the system. QIAsymphony gives customers access to a broad range of commercially available assays while also allowing them to run laboratory-developed tests (LDTs), which often account for more than half the volume of molecular testing in a typical laboratory. Additional features include continuous loading, random access and the ability to process an almost unlimited range of sample types.

Approximately 70% of all QIAsymphony systems placed through the end of 2012 have been with Molecular Diagnostics customers, and primarily to these customers through reagent rental agreements where revenues are recognized over a multi-year period. In the Life Sciences customer classes, which account for approximately 30% of placements, demand has also been strong among Applied Testing customers (human ID/forensics, food safety and veterinary medicine), particularly following the launch of new QIAsymphony protocols for these applications in early 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qiagen Bids $100M to Acquire Exiqon
Transaction will expand leadership position in RNA technologies.
Thursday, March 31, 2016
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, BGI Tech Database Agreement
BGI Tech will provide services to the Greater China market with the widely used HGMD literature source.
Friday, August 01, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Acquires CLC Bio
This acquisition enables QIAGEN to create a complete workflow from biological sample to valuable molecular insights.
Wednesday, October 30, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN to Acquire SABiosciences
Transaction adds to QIAGEN’s content engine for development of future diagnostics and boosts the Company’s presence in pharma discovery and validation.
Tuesday, November 10, 2009
Scientific News
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Spotting DNA Repair Genes Gone Awry
Ludwig researchers develop a two-pronged approach for identifying genes responsible for fixing DNA damage that can trigger cancer when compromised.
Interpreting “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome.
A Programming Language for Living Cells
New language lets researchers design novel biological circuits.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!